An important component of severe COVID-19 disease is virus-induced endothelilitis. This
leads to disruption of normal endothelial function, initiating a state of failing normal clotting …

Increasing environmental distress is associated with a growing asthma incidence; no
treatments are available but montelukast (MTK)—an antagonist of the cysteinyl leukotrienes …

Lung and hematopoietic stem cell transplantation are therapeutic modalities in chronic
pulmonary and hematological diseases, respectively. One of the complications in these …

Abstract Coronavirus disease 2019 (Covid‐19) is caused by a novel severe acute
respiratory syndrome coronavirus virus type 2 (SARS‐CoV‐2) leading to the global …

The coronavirus helicase is an essential enzyme required for viral replication/transcription
pathways. Structural studies revealed a sulphate moiety that interacts with key residues …

Introduction Montelukast is a leukotriene inhibitor that is widely used to treat chronic asthma
and allergic rhinitis. The drug interferes with molecular signaling pathways produced by …

Abstract Background Cysteinyl leukotrienes (CysLT) are potent inflammation-promoting
mediators, but remain scarcely explored in COVID-19. We evaluated urinary CysLT (U …

At its introduction in the management of pediatric asthma, montelukast was regarded as a
potentially revolutionary drug due to its mechanism of action and easy clinical applicability …

Repurposing off-label drugs during epidemics or pandemics with unknown/known
pathogens, particularly when their side effects and complications are already known, can be …

Introduction: COVID-19 is associated with a cascade of inflammatory responses potentially
lead to devastating outcomes. Objectives: The current study aims to investigate the efficacy …